Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16029336 | 0.89 | TRPC1 (0.54) | MAOAMAOBNCOA3NCOA1HTT | |
| SCHEMBL19560416 | 0.81 | THRB (0.71) | MAOAMAOBNCOA3NCOA1HTT | |
| SCHEMBL16029723 | 0.81 | LMNA (0.53) | MAOAMAOBHTTLMNAALDH1A1 | |
| SCHEMBL16076199 | 0.81 | TRPC5 (0.57) | NCOA3NCOA1HTTLMNAMEN1 | |
| SCHEMBL16028858 | 0.80 | TRPC5 (0.56) | NCOA3NCOA1HTTLMNAMEN1 | |
| SCHEMBL17772701 | 0.80 | ALDH1A1 (0.56) | MAOAMAOBNCOA3NCOA1HTT | |
| SCHEMBL16029849 | 0.80 | TRPC4 (0.64) | MAOAMAOBNCOA3NCOA1HTT | |
| SCHEMBL16076171 | 0.80 | TRPC5 (0.60) | NCOA3NCOA1HTTLMNAMEN1 | |
| SCHEMBL16029510 | 0.79 | ALDH1A1 (0.57) | MAOAMAOBNCOA3NCOA1HTT | |
| SCHEMBL16029247 | 0.79 | ALDH1A1 (0.65) | MAOAMAOBNCOA3NCOA1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970316-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | MAOA 886/4885MAOB 518/4885NCOA3 2717/4885 |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | MAOA 886/4885MAOB 518/4885NCOA3 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.